explore -WSS

explore

author：entertainment 2025-09-29 01:08:43 - browse：8317

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Ukraine taking heavy casualties 10 weeks into its counteroffensive

WSS

Designating disabled people as health disparity population is crucial

New definition of a human embryo proposed amid rapid advances

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

FDA approves first treatment for ultra

Congress must give Medicare recipients genetic counseling access

leisure time

explore

focus

At least 13 dead in Texas as scorching temps continue

Liz Cheney makes 1st public comment since Trump's election interference indictments

Apple is now the first public company to be valued at $3 trillion

DeSantis can now import cheaper drugs. But will Biden get credit?

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Novavax promises a turnaround & Lilly roils the obesity market

Living with Hashimoto's and celiac disease, and med school, too

knowledge

The pain doctors face in trying to build their families

New definition of a human embryo proposed amid rapid advances

ActiGraph execs on goal of drug approvals with digital endpoints

Congress must give Medicare recipients genetic counseling access

Biotech reporter’s notebook: A sunnier mood at JPM 2024

New definition of a human embryo proposed amid rapid advances

Wikipedia

explore

leisure time

knowledge